GlassScriptPhysician profile
Michelle A Putnam
NPI 1063584092
$5,273.40
in general payments reported to CMS, 2019-2025
20 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 81% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $252 · 2021: $1,577 · 2022: $662 · 2023: $735 · 2024: $552 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,396.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,422.58 | 2019-2025 | Xpress Ent Dilation System, Xpress Loprofile, Cyclone Sinonasal Suction/Irrigation System |
| Aerin Medical INC. | $835.69 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $618.11 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $573.11 | 2021-2025 | Nucala |
| Merz North America, INC. | $400.94 | 2021-2025 | |
| Genzyme Corporation | $273.89 | 2023-2025 | |
| Acclarent, INC | $178.20 | 2019-2023 | Trudi Nav Cable |
| Abbvie INC. | $172.95 | 2023-2025 | |
| Neurent Medical Limited | $150.95 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Optinose US, INC. | $125.03 | 2022-2025 | |
| Medtronic, INC. | $99.34 | 2023-2025 | Propel |
| Smith+Nephew, INC. | $92.05 | 2019-2024 | Halo, Tula, Coblation |
| Hikma Pharmaceuticals USA | $75.61 | 2022-2024 | Ryaltris |
| Intersect Ent, INC. | $67.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $63.13 | 2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49.15 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $26.40 | 2023 | |
| Organogenesis INC. | $18.84 | 2023 | Puraply |
| Kaleo, INC. | $17.74 | 2021 | |
| Karl Storz Endoscopy-America | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Putnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.